Entry Or Fusion Inhibitors - Infectious Diseases

Relevant Publications

Tubeimosides are pan-coronavirus and filovirus inhibitors that can block their fusion protein binding to Niemann-Pick C1.

Issue Release: 2024

A stapled lipopeptide platform for preventing and treating highly pathogenic viruses of pandemic potential.

Issue Release: 2024

Natural Variation in HIV-1 Entry Kinetics Map to Specific Residues and Reveal an Interdependence Between Attachment and Fusion.

Issue Release: 2024

A Quantitative Fusion Assay to Study Measles Virus Entry.

Issue Release: 2024

Research Progress on Spike-Dependent SARS-CoV-2 Fusion Inhibitors and Small Molecules Targeting the S2 Subunit of Spike.

Issue Release: 2024

Novel proteolytic activation of Ebolavirus glycoprotein GP by TMPRSS2 and cathepsin L at an uncharted position can compensate for furin cleavage.

Issue Release: 2024

Strategic Design of Tryptophan-Aspartic Acid-Containing Peptide Inhibitors Using Coronin 1 as a Template: Inhibition of Fusion by Enhancing Acyl Chain Order.

Issue Release: 2024

Dynamin independent endocytosis is an alternative cell entry mechanism for multiple animal viruses.

Issue Release: 2024

Entry inhibitors as arenavirus antivirals.

Issue Release: 2024

Proprotein convertase cleavage of Ictalurid herpesvirus 1 spike-like protein ORF46 is modulated by N-glycosylation.

Issue Release: 2024

Targetable domains for the design of peptide-dendrimer inhibitors of SARS-CoV-2.

Issue Release: 2024

Harringtonine metabolites: 5\'-de-O-methylharringtonine and cephalotaxine, targeting spike protein and TMPRSS2 to double block membrane fusion of SARS-CoV-2 and its variants.

Issue Release: 2024

A New Chimeric Antibody against the HIV-1 Fusion Inhibitory Peptide MT-C34 with a High Affinity and Fc-Mediated Cellular Cytotoxicity.

Issue Release: 2024

Comparison of SARS-CoV-2 entry inhibitors based on ACE2 receptor or engineered Spike-binding peptides.

Issue Release: 2023

Repurposing and discovery of transmembrane serine protease 2 (TMPRSS2) inhibitors as prophylactic therapies for new coronavirus disease 2019 (COVID-19).

Issue Release: 2023

An overview of the recent progress in Middle East Respiratory Syndrome Coronavirus (MERS-CoV) drug discovery.

Issue Release: 2023

A Pseudovirus-Based Entry Assay to Evaluate Neutralizing Activity against Respiratory Syncytial Virus.

Issue Release: 2023

SARS-CoV-2 Omicron entry is type II transmembrane serine protease-mediated in human airway and intestinal organoid models.

Issue Release: 2023

The Ubiquitin-Proteasome System Facilitates Membrane Fusion and Uncoating during Coronavirus Entry.

Issue Release: 2023

SARS-CoV-2 Omicron XBB subvariants exhibit enhanced fusogenicity and substantial immune evasion in elderly population, but high sensitivity to pan-coronavirus fusion inhibitors.

Issue Release: 2023

What are Immunodeficiency Disorders?

Why are Drug Targets Important?

What Role Does Epidemiology Play in Outbreaks?

What Role Does Technology Play in Infectious Disease Education?

What are the Symptoms in Humans?

How Does Viral Interference Occur?

What Are the Complications of Herpes?

What Diseases are Transmitted by Culex Mosquitoes?

Why is RT-PCR important in Infectious Diseases?

What are the Achievements of the RBM Partnership?

Partnered Content Networks

Relevant Topics